Datopotamab deruxtecan clinical trials
7 indexed studies · 2 currently recruiting
- RecruitingTherapeutic exploratory (Phase II)
Phase 2, Single-arm, Open-label Study of DS1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed on or After Applicable Targeted Therapy and Platinumbased Chemotherapy (TROPION-Lung05)
This study looks at a new drug, Datopotamab deruxtecan, for people with advanced lung cancer that has specific genetic changes and hasn't responded to previous treatments. Researchers want to see how many people's tumours shrink or disappear after taking the drug.
For: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Netherlands · France · Spain - Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
For: Metastatic Non Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - Active not recruitingPHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is looking at a new combination of medicines, Dato-DXd and pembrolizumab, for advanced lung cancer. It compares this combination to pembrolizumab alone to see if it's more effective and safe for people whose cancer hasn't spread and who haven't had other treatments yet.
For: Metastatic Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
This study looks at new treatments for early-stage lung cancer after surgery. It compares new drug combinations against standard care to see if they can stop the cancer from coming back, especially in people with higher risk.
For: Non-small Cell Lung CancerUnited States · Brazil · Canada